Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial.
Cancer Discov. 2023 Nov 1;13(11):2394-2411. doi: 10.1158/2159-8290.CD-23-0436.
Cancer Discov. 2023.
PMID: 37707791
Free PMC article.
Clinical Trial.
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer.
Herbst RS, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, Sanchez-Hernandez A, Dakhil S, Camidge DR, Winzer L, Soo-Hoo Y, Cooper ZA, Kumar R, Bothos J, Aggarwal C, Martinez-Marti A.
Herbst RS, et al. Among authors: soo hoo y.
J Clin Oncol. 2022 Oct 10;40(29):3383-3393. doi: 10.1200/JCO.22.00227. Epub 2022 Apr 22.
J Clin Oncol. 2022.
PMID: 35452273
Clinical Trial.
Item in Clipboard
Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir.
Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG.
Gubareva LV, et al. Among authors: soo hoo y.
J Infect Dis. 2001 Feb 15;183(4):523-31. doi: 10.1086/318537. Epub 2001 Jan 11.
J Infect Dis. 2001.
PMID: 11170976
Clinical Trial.
Item in Clipboard
Cite
Cite